AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialAbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral Share XAbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialhttps://pharmaphorum.com/news/abbvie-preps-filings-after-abbv-951-tops-oral-parkinsons-drugs-in-trial/
Supernus bulks up its Parkinson’s portfolio with Adamas takeoverSupernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Share XSupernus bulks up its Parkinson’s portfolio with Adamas takeoverhttps://pharmaphorum.com/news/supernus-bulks-up-its-parkinsons-portfolio-with-adamas-takeover/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapyBayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based Share XFDA gives speedy review to Bayer’s Parkinson’s stem cell therapyhttps://pharmaphorum.com/news/fda-gives-speedy-review-to-bayers-parkinsons-stem-cell-therapy/
Ipsen tries again in Parkinson’s disease with $363m IRLAB dealFrench drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine Share XIpsen tries again in Parkinson’s disease with $363m IRLAB dealhttps://pharmaphorum.com/news/ipsen-tries-again-in-parkinsons-disease-with-363m-irlab-deal/
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinicBayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its Share XBayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinichttps://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/
Cambridge Sleep Sciences’ device is trialled in Parkinson’sSleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people Share XCambridge Sleep Sciences’ device is trialled in Parkinson’shttps://pharmaphorum.com/news/cambridge-sleep-sciences-device-is-trialled-in-parkinsons/
AI drug discovery firm Valence joins Parkinson’s disease pushCanada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat Share XAI drug discovery firm Valence joins Parkinson’s disease pushhttps://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/
Patients as Partners Europe: Are we doing patient centricity all wrong?To be truly patient centric, do we need to turn the current model on its head and work Share XPatients as Partners Europe: Are we doing patient centricity all wrong?https://pharmaphorum.com/views-analysis-patients/pharma-patients-as-partners-europe-patient-centricity/
